Speaker Profile
M.D., Senior Vice President, Medical, Castle Biosciences
Biography
Dr. Matthew Goldberg has been with Castle Biosciences since August 2020. Prior to joining Castle, Goldberg was an Assistant Professor in Dermatology and Pathology at the Icahn School of Medicine at Mount Sinai in New York and retains his affiliation as an Assistant Clinical Professor of Dermatology. Prior to that, he directed dermatopathology education for the MedStar GeorgetownWashington Hospital Center dermatology residency program. Goldberg has a background in translational melanoma research and received the Dermatology Foundation Dermatopathology Research Career Development Award for his research in the field of melanoma epigenetics.Goldberg graduated summa cum laude from Princeton University and received his medical degree from the Icahn School of Medicine at Mount Sinai, where he graduated with distinction in research. He completed his dermatology residency at the University of California, San Francisco, and completed a dermatopathology fellowship at the University of Texas Southwestern. Dr. Goldberg is board certified in dermatology and dermatopathology.
Talk
Improving Patient Care and Outcomes Using Advanced Genomics
Advanced molecular diagnostics are shifting the treatment paradigm for patients with cancers by enabling personalized and riskaligned disease management decisions. This talk will explore the potential of genomic testing in skin cancers to guide more informed patient care decisions that can improve patient outcomes.
Genomic Profiling Showcase:
Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company focused on improving health through innovative tests that guide patient care. Castle’s current portfolio consists of tests for skin cancers, uveal melanoma, Barrett’s esophagus and mental health conditions.
Session Abstract – PMWC 2024 Silicon Valley
The PMWC 2024 Genomic Profiling Showcase will provide a 15 min speaking opportunity for selected companies working with the latest technologies in nucleic acid sequencing such as NGS, providing instrumentation for genomic sequencing, and offering direct to consumer services. These companies will share their innovative products and services to an audience of leading investors, potential clients and partners. The Genomic Profiling Showcase will exhibit the latest innovations in methods and instruments used for DNA/ RNA sequencing to ascertain the genomic and transcriptional profile of a person in order to understand why some people get certain diseases while others do not, or why people react in different ways to the same drug. This information is also being used to develop new ways to diagnose, treat, and prevent diseases, such as cancer.
